<h2 data-section-id="znhwv6" data-start="0" data-end="12"><strong>Acute Kidney Injury Market</strong></h2>
<p data-start="13" data-end="660">The <a href="https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market"><strong>Acute Kidney Injury (AKI) market</strong></a> is witnessing steady growth due to the increasing burden of hospital-acquired kidney complications and rising prevalence of chronic diseases. In 2025, the AKI market size across the 7MM was valued at nearly USD 4.9 billion and is projected to grow at a CAGR of 4.1% during 2026&ndash;2036. Current treatment mainly relies on supportive care, renal replacement therapy (RRT), and off-label drugs, while TERLIVAZ remains the only FDA-approved targeted therapy for HRS-AKI. Growing adoption of advanced diagnostics and biomarker-based monitoring is expected to improve patient management and commercial opportunities.</p>
<ul data-start="662" data-end="843">
<li data-section-id="1fvin0z" data-start="662" data-end="702">Market size in 2025: USD 4.9 billion</li>
<li data-section-id="1qcjwdf" data-start="703" data-end="738">Forecast CAGR (2026&ndash;2036): 4.1%</li>
<li data-section-id="1isrdq4" data-start="739" data-end="791">TIN816 expected to dominate Japan market by 2036</li>
<li data-section-id="1uzqta" data-start="792" data-end="843">Rising nephrotoxic drug exposure driving demand</li>
</ul>
<h2 data-section-id="1uvesjx" data-start="845" data-end="863"><strong>Acute Kidney Injury Epidemiology</strong></h2>
<p data-start="864" data-end="1573">Acute Kidney Injury represents a major healthcare burden globally, particularly among hospitalized patients. In 2025, total incident AKI cases across the 7MM reached nearly 23 million, with the US accounting for 5.2 million mortality-adjusted incident cases. AKI commonly occurs in critically ill patients, especially those with sepsis and cardiovascular complications. Stage I AKI represented the highest proportion of cases, followed by Stage II and Stage III disease. Increasing hospitalization rates and aging populations continue to expand the eligible patient pool for emerging therapies. The disease also demonstrates strong association with intensive care admissions and postoperative complications.</p>
<ul data-start="1575" data-end="1805">
<li data-section-id="xbhq8s" data-start="1575" data-end="1618">Total incident cases in 7MM: 23 million</li>
<li data-section-id="nbe8ju" data-start="1619" data-end="1663">US mortality-adjusted cases: 5.2 million</li>
<li data-section-id="6lo7al" data-start="1664" data-end="1697">AKI prevalence in sepsis: 66%</li>
<li data-section-id="3einyv" data-start="1698" data-end="1720">HRS-AKI cases: 11%</li>
<li data-section-id="1w9kl22" data-start="1721" data-end="1748">CSA-AKI prevalence: 12%</li>
<li data-section-id="6zaggo" data-start="1749" data-end="1776">CABG-AKI prevalence: 7%</li>
<li data-section-id="cba78c" data-start="1777" data-end="1805">Contrast-induced AKI: 3%</li>
</ul>
<h2 data-section-id="10hi5us" data-start="1807" data-end="1821"><strong>Acute Kidney Injury Pipeline</strong></h2>
<p data-start="1822" data-end="2591">The <a href="https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight"><strong>AKI pipeline</strong></a> is evolving with several companies developing targeted therapies aimed at reducing inflammation, oxidative stress, and renal injury progression. Despite repeated clinical setbacks, emerging therapies are focused on improving renal recovery and reducing dialysis dependence. Key players such as <span class="whitespace-normal">AstraZeneca</span>, <span class="whitespace-normal">Renibus Therapeutics</span>, and <span class="whitespace-normal">Alloksys Life Sciences</span> are advancing novel candidates in clinical development. The approval of TERLIVAZ has strengthened confidence in regulatory success for acute renal conditions, encouraging broader investment in the AKI therapeutic landscape. Biomarker-driven stratification and outcome-focused studies are expected to shape future development strategies.</p>
<h3 data-start="2593" data-end="2613"><strong data-start="2593" data-end="2611">Emerging Drugs</strong></h3>
<ul data-start="2614" data-end="2901" data-is-last-node="" data-is-only-node="">
<li data-section-id="1x1arh4" data-start="2614" data-end="2667">Ravulizumab (<a href="https://www.delveinsight.com/report-store/ultomiris-emerging-drug-insight-and-market-forecast"><strong>ULTOMIRIS</strong></a>) &ndash; <a href="https://www.delveinsight.com/report-store/complement-c5-inhibitors-pipeline-insight"><strong>Complement C5 inhibitor</strong></a></li>
<li data-section-id="1rrf20p" data-start="2668" data-end="2729">RBT-1 &ndash; <a href="https://www.delveinsight.com/report-store/anti-inflammatory-drugs-market"><strong>Anti-inflammatory</strong></a> and antioxidant pathway inducer</li>
<li data-section-id="1borhlx" data-start="2730" data-end="2791">RESCAP (<a href="https://www.delveinsight.com/report-store/brescap-emerging-drug-insight-and-market-forecast"><strong>bRESCAP</strong></a>) &ndash; Prophylactic anti-inflammatory therapy</li>
<li data-section-id="ekzit1" data-start="2792" data-end="2846">Focus on reducing ICU stay and dialysis initiation</li>
<li data-section-id="1nnu79g" data-start="2847" data-end="2901" data-is-last-node="">Increasing interest in precision-based AKI therapies</li>
</ul>

Acute Kidney Injury  Market

Acute Kidney Injury Market Infographic

Acute Kidney Injury Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.